“Comparison of Study Designs for Primary Phase III Trials for Omalizumab Versus Dupilumab for Patients With Chronic Spontaneous Urticaria”, J of Skin, vol. 8, no. 1, p. s333, Jan. 2024, doi: 10.25251/skin.8.supp.333.